Market closedNon-fractionalADR

Renalytix/RNLX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Renalytix

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Ticker

RNLX

Sector

Healthcare

Trading on

NASDAQ

Industry

Software & Programming

Headquarters

London, United Kingdom

Employees

102

Renalytix Metrics

BasicAdvanced
$32M
Market cap
-
P/E ratio
-$0.78
EPS
2.89
Beta
-
Dividend rate
$32M
2.89
$4.04
$0.24
16
0.423
-8.74%
-154.36%
-1,073.18%
-396.70%
14.609
-40.23%
23.08%

What the Analysts think about Renalytix

Analyst Ratings

Majority rating from 2 analysts.
Buy

Renalytix Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,540.00% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$500K
-28.57%
Net income
-$7.7M
-8.33%
Profit margin
-1,540.00%
28.33%

Renalytix Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 6.67%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.24
-$0.22
-$0.18
-$0.08
-
Expected
-$0.13
-$0.10
-$0.09
-$0.08
-$0.08
Surprise
89.47%
120.00%
100.00%
6.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Renalytix stock?

Renalytix (RNLX) has a market cap of $32M as of July 06, 2024.

What is the P/E ratio for Renalytix stock?

The price to earnings (P/E) ratio for Renalytix (RNLX) stock is 0 as of July 06, 2024.

Does Renalytix stock pay dividends?

No, Renalytix (RNLX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Renalytix dividend payment date?

Renalytix (RNLX) stock does not pay dividends to its shareholders.

What is the beta indicator for Renalytix?

Renalytix (RNLX) has a beta rating of 2.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Renalytix stock

Buy or sell Renalytix stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing